ELE vs RPRX
ELE: A precious metals royalty company that provides capital to mining operators in exchange for diversified streams of gold and mineral production. RPRX: Royalty Pharma is the leading financier of pharmaceutical innovation, providing capital in exchange for long-term royalty streams on top-tier commercial drug therapies.
Side-by-side fundamentals
| Metric | ELE | RPRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.87 | $58.72 | |
| Market cap as of 2026-07-23 | $1.5B | $33.8B | |
| P/E as of 2026-07-23 | 583.83 | 40.88 | RPRX lower |
| PEG as of 2026-07-23 | n/a | 3.37 | |
| Net margin as of 2026-07-23 | -1.1% | +33.9% | RPRX higher |
| Gross margin as of 2026-07-23 | +60.8% | n/a | |
| Operating margin as of 2026-07-23 | +13.4% | +65.1% | RPRX higher |
| ROE as of 2026-07-23 | -0.1% | +12.7% | RPRX higher |
| ROA as of 2026-07-23 | -0.1% | +4.3% | RPRX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.30 | ELE lower |
| Revenue growth (YoY) as of 2026-07-23 | +128.6% | +7.8% | ELE higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +2.1% | |
| Dividend yield as of 2026-07-23 | +0.5% | +1.6% | RPRX higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 2.48 | 0.43 | |
| 1-year return as of 2026-07-22 close | +7.6% | +62.7% | RPRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.